FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc.

$10.32

+0.12 +1.18% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 11:20 AM ET	10.32

Key Stats

Market Cap

361.89M

Avg Volume

195,362

EPS

-$0.12

52W High

$13.25

52W Low

$5.65

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

10.89

P/B Ratio

8.52

P/S Ratio

6.11

EV/EBITDA

-309.83

EV/Revenue

5.34

PEG Ratio

1.47

Margins

Gross Margin 93.7%

Operating Margin 9.7%

Net Margin (5.5%)

EBITDA Margin (1.7%)

Growth & Returns

Revenue Growth (YoY)

85.2%

Return on Equity

(18.6%)

Return on Assets

(1.2%)

Liquidity & Leverage

Current Ratio

5.85

Quick Ratio

5.21

Total Cash

41.25M

Total Debt

About

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.